Skip to main content
Home

Main navigation

  • Home
  • News
  • About HIV
  • About us
  • Donate
Search
Donate now

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you.

I am a UK taxpayer and I understand that if I pay less Income and /or Capital Gains Tax than the amount of Gift Aid claimed on all my donations in the relevant tax year, it is my responsibility to pay any difference.

In our 35th year we’re asking people to donate £35 – that’s just £1 for every year we’ve been providing life-changing information. Any donation you make helps us continue our work towards a world where HIV is no longer a threat to health or happiness.

  • £5 allows us to reach millions of people globally with accurate and reliable resources about HIV prevention and treatment.
  • £10 helps us produce news and bulletins on the latest developments in HIV for healthcare staff around the world.
  • £35 means we can empower more people living with HIV to challenge stigma with our information workshops, videos and broadcasts.
Conferences

ICAAC 2011

The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) was held in Chicago in September 2011.
The search for a cure

Gene therapy for HIV is “progress towards functional cure” say researchers

20 September 2011
New & experimental hepatitis C treatment

New anti-hepatitis C drug BMS-790052 does well in Phase IIa study

20 September 2011
Changing treatment

Switching to once-daily etravirine a safe and effective option for individuals taking suppressive protease inhibitor therapy

20 September 2011
Changing treatment

A fifth of patients discontinue Atripla within a year, CNS side-effects the main reason

19 September 2011
Resistance

Big falls in prevalence of protease inhibitor and triple-class resistance

19 September 2011
Sign up for our email bulletins.
Sign up

Editors’ picks from other sources

New & experimental hepatitis C treatment

ICAAC: HCV Drug Telaprevir Shows No Problematic Interactions with Raltegravir

The new hepatitis C virus (HCV) protease inhibitor telaprevir (Incivek) does not appear to have clinically relevant drug-drug interactions with the HIV integrase inhibitor raltegravir (Isentress), according to a study presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) last month in Chicago.
HIVandhepatitis.com
6 Oct 11
Treatment outcomes & life expectancy

ICAAC: One-Pill HIV Regimen Tied to Less Inpatient Care

Low-income HIV patients on a single-pill regimen had about a 25% lower risk of hospitalization over time than those taking multiple pills, a researcher said here.
MedPage Today HIV/AIDS
23 Sep 11
New & experimental HIV treatments

ICAAC: HIV-2 May Yield to Integrase Inhibitor

A drug aimed at patients with the most common form of HIV also appears to be effective in those with a less widespread form, a researcher said here.
MedPage Today HIV/AIDS
22 Sep 11
New & experimental HIV treatments

Ibalizumab Study Casts a Ray of Hope for HIV-Infected People With Extensive Drug Resistance

Ibalizumab, formerly TNX-355, is a monoclonal antibody designed to prevent HIV entry. A phase IIb study of the drug was presented at ICAAC by TaiMed Biologics, the new developer of the drug.
The Body
21 Sep 11
The search for a cure

"Functional Cure" For HIV/AIDS Glimpsed In Small Trial

Researchers testing a potential new gene therapy for HIV/AIDS say they are excited by early results that represent significant progress towards a "functional cure" for the disease.
HIV / AIDS News From Medical News Today
19 Sep 11
New & experimental HIV treatments

Sangamo’s Blood-Cell Gene Therapy Fights HIV Without Drugs

Gene therapy developed by Sangamo Bioscience Inc. to mimic the blocking effect of white blood cells in people naturally immune to HIV helped six patients fight off the disease without drugs, a study showed.
Bloomberg Business Week
19 Sep 11
New & experimental HIV treatments

Sangamo gene therapy shows promise in reducing HIV

An early stage trial of Sangamo BioSciences Inc's HIV treatment found that the gene therapy reduced levels of the virus and even eliminated it in one patient with a naturally occurring gene mutation.
Reuters
19 Sep 11
More editors' picks

About us

Our information is intended to support, rather than replace, consultation with a healthcare professional.

Talk to your doctor or another member of your healthcare team for advice tailored to your situation.

Connect with us

  • Twitter
  • Facebook
  • YouTube
  • Instagram

Links

Show — Links Hide — Links
  • Contact us
  • THT Direct Helpline
  • Subscribe to email bulletins

 

aidsmap (previously known as NAM aidsmap) is now hosted by Terrence Higgins Trust, an HIV charity based in the United Kingdom.

 

Copyright 2025 © Terrence Higgins Trust is a registered charity in England and Wales (reg. no. 288527) Company reg. no. 1778149 and a registered charity in Scotland (reg. no. SC039986). Registered office: 437 & 439 Caledonian Road, London, N7 9BG.

Footer menu

Show — Footer menu Hide — Footer menu
  • Accessibility
  • Compliment, complaint or concern
  • Our information
  • Privacy & cookies
  • Terms of use
  • Terrence Higgins Trust